Cargando…

Associations Between Soluble fms‐Like Tyrosine Kinase‐1 and Placental Growth Factor and Disease Severity Among Women With Preterm Eclampsia and Preeclampsia

BACKGROUND: The angiogenic factors soluble fms‐like tyrosine kinase‐1 (sFlt‐1) and placental growth factor (PlGF) are postulated to be pathogenic disease drivers of preeclampsia. If true, then circulating levels should become more deranged with increasing disease severity. METHODS AND RESULTS: We in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hastie, Roxanne, Bergman, Lina, Walker, Susan P., Kaitu'u‐Lino, Tu'uhevaha, Hannan, Natalie J., Brownfoot, Fiona, Schell, Sonja, Harper, Alesia, Cannon, Ping, Cluver, Catherine A., Tong, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496300/ https://www.ncbi.nlm.nih.gov/pubmed/35943054 http://dx.doi.org/10.1161/JAHA.121.024395

Ejemplares similares

Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta
por: Brownfoot, Fiona C., et al.
Publicado: (2016)

Resveratrol inhibits release of soluble fms-like tyrosine kinase (sFlt-1) and soluble endoglin and improves vascular dysfunction – implications as a preeclampsia treatment
por: Hannan, Natalie J., et al.
Publicado: (2017)

Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction
por: Brownfoot, Fiona C., et al.
Publicado: (2019)

Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction – implications for treating preeclampsia
por: Kaitu’u-Lino, Tu’uhevaha J., et al.
Publicado: (2018)

Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia
por: Hannan, Natalie J., et al.
Publicado: (2018)

Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy
por: Hastie, Roxanne, et al.
Publicado: (2018)

Placental galectin-3 is reduced in early-onset preeclampsia
por: Kandel, Manju, et al.
Publicado: (2022)

Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial
por: Cluver, Catherine A, et al.
Publicado: (2021)

A double blind, randomised, placebo-controlled trial to evaluate the efficacy of metformin to treat preterm pre-eclampsia (PI2 Trial): study protocol
por: Cluver, Catherine, et al.
Publicado: (2019)

Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks’ gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study
por: MacDonald, Teresa M., et al.
Publicado: (2018)

PSG7 and 9 (Pregnancy‐Specific β‐1 Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia
por: Kandel, Manju, et al.
Publicado: (2022)

Circulating Chemerin Is Elevated in Women With Preeclampsia
por: Bartho, Lucy A, et al.
Publicado: (2023)

Circulating SPINT1 Is Reduced in a Preeclamptic Cohort with Co-Existing Fetal Growth Restriction
por: Murphy, Ciara N., et al.
Publicado: (2022)

Clinical tools and biomarkers to predict preeclampsia
por: MacDonald, Teresa M, et al.
Publicado: (2021)

Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin
por: Whigham, Carole-Anne, et al.
Publicado: (2019)

Therapeutic interventions: The importance of including diseased and healthy samples in preclinical studies
por: Tu'uhevaha J., Kaitu'u-Lino
Publicado: (2019)

MMP-15 Is Upregulated in Preeclampsia, but Does Not Cleave Endoglin to Produce Soluble Endoglin
por: Kaitu’u-Lino, Tu’uhevaha J., et al.
Publicado: (2012)

Measuring circulating miRNAs in early pregnancy could identify fetuses’ destined to undergrow and be at increased risk of stillbirth
por: Tong, Stephen, et al.
Publicado: (2020)

Paternal Expressed Gene 10 (PEG10) is decreased in early-onset preeclampsia
por: Baird, Lydia, et al.
Publicado: (2023)

Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker
por: Cruickshank, Tess, et al.
Publicado: (2021)

Placental Growth Factor Is Secreted by the Human Endometrium and Has Potential Important Functions during Embryo Development and Implantation
por: Binder, Natalie K., et al.
Publicado: (2016)

Placental OLAH Levels Are Altered in Fetal Growth Restriction, Preeclampsia and Models of Placental Dysfunction
por: de Alwis, Natasha, et al.
Publicado: (2022)

Evidence of Neuroinflammation and Blood–Brain Barrier Disruption in Women with Preeclampsia and Eclampsia
por: Bergman, Lina, et al.
Publicado: (2021)

A comparison of sample collection methods for quantifying cell-free fetal neurodevelopment transcripts in amniotic fluid
por: Hui, Lisa, et al.
Publicado: (2016)

Actions of Esomeprazole on the Maternal Vasculature in Lean and Obese Pregnant Mice with Impaired Nitric Oxide Synthesis: A Model of Preeclampsia
por: de Alwis, Natasha, et al.
Publicado: (2022)

Investigating the Effects of Atrial Natriuretic Peptide on the Maternal Endothelium to Determine Potential Implications for Preeclampsia
por: Binder, Natalie K., et al.
Publicado: (2023)

Assessment of the Proton Pump Inhibitor, Esomeprazole Magnesium Hydrate and Trihydrate, on Pathophysiological Markers of Preeclampsia in Preclinical Human Models of Disease
por: de Alwis, Natasha, et al.
Publicado: (2022)

Pre-Clinical Investigation of Cardioprotective Beta-Blockers as a Therapeutic Strategy for Preeclampsia
por: Binder, Natalie K., et al.
Publicado: (2021)

The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health
por: de Alwis, Natasha, et al.
Publicado: (2022)

Screening circulating proteins to identify biomarkers of fetal macrosomia
por: Cruickshank, Tess, et al.
Publicado: (2019)

Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction
por: Kaitu’u-Lino, Tu’uhevaha J., et al.
Publicado: (2020)

ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia
por: Pritchard, Natasha, et al.
Publicado: (2018)

Serum Collected from Preeclamptic Pregnancies Drives Vasoconstriction of Human Omental Arteries—A Novel Ex Vivo Model of Preeclampsia for Therapeutic Development
por: Fato, Bianca R., et al.
Publicado: (2022)

A Bioplex Analysis of Cytokines and Chemokines in First Trimester Maternal Plasma to Screen for Predictors of Miscarriage
por: Hannan, Natalie J., et al.
Publicado: (2014)

MicroRNAs 363 and 149 are differentially expressed in the maternal circulation preceding a diagnosis of preeclampsia
por: Whigham, Carole-Anne, et al.
Publicado: (2020)

Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
por: Bartho, Lucy A., et al.
Publicado: (2023)

Evaluation of ADAM-12 as a Diagnostic Biomarker of Ectopic Pregnancy in Women with a Pregnancy of Unknown Location
por: Horne, Andrew W., et al.
Publicado: (2012)

Elevated Circulating and Placental SPINT2 Is Associated with Placental Dysfunction
por: Murphy, Ciara N., et al.
Publicado: (2021)

Serum Concentrations of Soluble Flt-1 Are Decreased among Women with a Viable Fetus and No Symptoms of Miscarriage Destined for Pregnancy Loss
por: Kaitu'u-Lino, Tu'uhevaha J., et al.
Publicado: (2012)

Plasma MIC-1 and PAPP-A Levels Are Decreased among Women Presenting to an Early Pregnancy Assessment Unit, Have Fetal Viability Confirmed but Later Miscarry
por: Kaitu’u-Lino, Tu’uhevaha J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1fmm92kogn8c305t82qpsluose